
    
      The end of the study is defined by a common study end date for all participants, defined as 9
      months (39 weeks) after the last participant randomized.

      All participants will receive oral warfarin (or matching placebo) and weekly SC injections of
      idrabiotaparinux sodium (or matching placebo) up to 6 months before the common study end
      date. All participants are expected to be treated for at least 6 months.

      All participants will have then an 6-month observational period after cessation of study
      treatment.
    
  